Jiangxi Fushine Pharmaceutical Co., Ltd.

Jiangxi Fushine Pharmaceutical Co., Ltd.

Jiangxi Fushine Pharmaceutical Co., Ltd.

Overview
Date Founded

2002

Headquarters

Junction of Yushan & Liyang,No. 2 Yuli Industrial Zone,Changjiang District,Jingdezhen, Jiangxi 333000

Type of Company

Public

Employees (Worldwide)

1,341

Industries

Pharmaceuticals
Retail: Drug Stores

Company Description

Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of active pharmaceutical ingredient (API) and pharmaceutical intermediates. It focuses on penicillin and its API and intermediates, and carbapenem and its API and intermediates. The company was founded in December 2002 and is headquartered in Jingdezhen, China.

Executives & Employees

Chairman

Director & Executive Deputy General Manager

General Manager

Director

Board of Directors

Chairman at Jiangxi Fushine Pharmaceutical Co., Ltd.

Vice President & Professor at Central University of Finance and Economics - China

Secretary at Changhong Huayi Compressor Co., Ltd.

Director at Jiangxi Fushine Pharmaceutical Co., Ltd.

Secretary & Vice President at China Chengxin Credit Management Co., Ltd.

Director & Executive Deputy General Manager at Jiangxi Fushine Pharmaceutical Co., Ltd.

Paths to Jiangxi Fushine Pharmaceutical Co., Ltd.
Potential Connections via
Relationship Science
You
Jiangxi Fushine Pharmaceutical Co., Ltd.
Recent Transactions
Details Hidden

Jiangxi Fushine Pharmaceutical Co., Ltd. issued Class A Common Stock

Details Hidden

Zhejiang Yongtai Technology Co., Ltd. purchases Jiangxi Fushine Pharmaceutical Co., Ltd.

Transaction Advisors
Underwriter

Advised onJiangxi Fushine Pharmaceutical Co., Ltd. issued Class A Common Stock

Clients

Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical raw materials and intermediates. Its business areas include: Non-contract manufacturing organization (CMO) business for active pharmaceutical ingredients (APIs) and intermediates, CMO business for APIs and intermediates, and Other. Its products are classified into API commercialized products such as losartan potassium, irbesartan, and valsartan; validated products such as apixaban, azilsartan, bosentan, and cinacalcet hydrochloride; products to be validated/under development such as aliskiren hemifumarate, azilsartan medoxomil, silodosin, and alogliptin benzoate; pharmaceutical intermediates including 2-Cyano-4'-methylbiphenyl, 2-Cyano-4-bromomethylbiphenyl, and N-Triphenylmethyl-5-4-bromomethylbiphenyl-2-yl-tetrazole; and fine chemicals such as N,N- Dicyclohexylcarbodiimide, 1-Ethy-3-3'-dimethylaminopropyl carbodiimide hydrochloride, and 2,6-Dichloroaniline. The company was founded on February 14, 2003 and is headquartered in Taizhou, China.

Key Stats and Financials As of 2017
Market Capitalization
$3.51B
Total Enterprise Value
$4.11B
Earnings Per Share
$0.79
Revenue
$949M
Net Profit
$178M
EBITDA
$256M
EBITDAMargin
26.98%
Total Debt
$593M
Total Equity
$967M
Enterprise Value Sales
4.33x
Enterprise Value EBITDAOperating
16.04x
TEVNet Income
23.14x
Debt TEV
0.14x
Three Year Compounded Annual Growth Rate Of Revenue
23.04%
Five Year Compounded Annual Growth Rate Of Revenue
21.43%
Investors
Details Hidden

Jiuding Capital is an active manager which invests in early-stage unlisted China-based companies operating in a range of sectors including electronics, communications, biotechnology, IT services, new energy, media, manufacturing, services and agricultural chemicals.The firm seeks to invest in well managed companies which are, or have the potential to become industry or regional market leaders. They prefer to participate in LBOs, growth and expansion capital investments, primarily through stock investment.Jiuding Capital typically takes minority stakes in their investee companies and contributes to major decision-making through board of director participation. They partner with their investee companies to provide value-added services including stock market listing assistance (in China or overseas), financial consulting, strategic planning assistance, corporate governance advice, internal structure and profit model optimization, tax planning and legal affairs and overseas marketing services.The firm aims to exit their investments through IPOs.